Houston Lands Texas’ First Major Pharma Plant with Eli Lilly $6.5B Investment

Eli Lilly and Company has announced a significant expansion of its manufacturing footprint with a $6.5 billion investment in a new pharmaceutical facility at Generation Park in Houston. The plans include a build-out of a 236-acre pharmaceutical manufacturing facility at Generation Park. The facility will produce active pharmaceutical ingredients (APIs), key components of Lilly’s medicines.  

This project marks the first major pharmaceutical manufacturing facility investment in Texas and is expected to create more than 600 full-time jobs with construction beginning this year and continue through 2030. 

“This win reflects years of strategic work by partners across the public and private sectors to build the talent, infrastructure, and business environment needed to attract world-class companies like Eli Lilly,” said Steve Kean, Greater Houston Partnership President and CEO. 

Eli Lilly joins a growing list of life sciences companies choosing Houston, including Cellipont Bioservices, PackGene, Lonza, United Therapeutics, and Bionova Scientific – reinforcing the region’s growth for-profit space, infrastructure, business environment and supportive ecosystem that makes it a rising leader in life sciences innovation.  

Learn more about Houston’s growing life sciences industry on our website.

https://www.houston.org/why-houston/industries/life-sciences-biotechnology/